| Literature DB >> 22629238 |
Saara Nuutinen1, Jenni Vanhanen, Tiia Mäki, Pertti Panula.
Abstract
The brain histaminergic system is one of the diffuse modulatory neurotransmitter systems which regulate neuronal activity in many brain areas. Studies on both rats and mice indicate that histamine H3 receptor antagonists decrease alcohol drinking in several models, like operant alcohol administration and drinking in the dark paradigm. Alcohol-induced place preference is also affected by these drugs. Moreover, mice lacking H3R do not drink alcohol like their wild type littermates, and they do not show alcohol-induced place preference. Although the mechanisms of these behaviors are still being investigated, we propose that H3R antagonists are promising candidates for use in human alcoholics, as these drugs are already tested for treatment of other disorders like narcolepsy and sleep disorders.Entities:
Keywords: H3 receptor; addiction; alcohol; conditioned place preference; drinking in the dark; histamine; reward; self-administration
Year: 2012 PMID: 22629238 PMCID: PMC3355329 DOI: 10.3389/fnsys.2012.00036
Source DB: PubMed Journal: Front Syst Neurosci ISSN: 1662-5137
Summary of the alterations in alcohol consumption and reward followed by manipulations of the brain histaminergic system.
| Model | Animal line/strain | Drug treatment | Result | Reference |
|---|---|---|---|---|
| Two-bottle choice | Alcohol-preferring P rats | JNJ-39220675 | Decrease in alcohol drinking | Galici et al. ( |
| Drinking in the dark | C57BL/6J | Ciproxifan | Lower alcohol consumption | Nuutinen et al. ( |
| Drinking in the dark | C57BL/6J | Immepip | Increased alcohol consumption | Nuutinen et al. ( |
| Two-bottle choice | H3R KO mice | – | Lower alcohol consumption | Nuutinen et al. ( |
| Drinking in the dark | H3R KO mice | – | Lower alcohol consumption | Nuutinen et al. ( |
| Two-bottle choice with 3-day alcohol deprivation | Alcohol-preferring P rats | JNJ-39220675 | Decrease in alcohol preference | Galici et al. ( |
| Self-administration | Alcohol-preferring AA rats | Thioperamide | Reduced lever presses for alcohol | Lintunen et al. ( |
| Self-administration | Alcohol-preferring AA rats | Clobenprobit | Reduced lever presses for alcohol | Lintunen et al. ( |
| Self-administration | Alcohol-preferring AA rats | R-α-methylhistamine | Increased lever presses for alcohol | Lintunen et al. ( |
| Self-administration | Alcohol-preferring AA rats | Mepyramine | No effect on alcohol lever presses | Lintunen et al. ( |
| Self-administration | Alcohol-preferring P rats | JNJ-39220675 | Reduced lever presses for alcohol | Galici et al. ( |
| Conditioned place preference | H3R KO mice | – | Inhibition of alcohol-induced place preference | Nuutinen et al. ( |
| Conditioned place preference | HDC KO mice | – | Stronger alcohol-induced place preference | Nuutinen et al. ( |
| Conditioned place preference | DBA/2J mice | Ciproxifan | Inhibition of alcohol-induced place preference | Nuutinen et al. ( |
| Conditioned place preference | 129/Sv mice | Ciproxifan | Stronger alcohol-induced place preference | Nuutinen et al. ( |
| Conditioned place preference | DBA/2J mice | JNJ-10181457 | Inhibition of alcohol-induced place preference | Nuutinen et al. ( |
| Conditioned place preference | DBA/2J mice | Immepip | No effect on alcohol-induced place preference | Nuutinen et al. ( |
HDC KO, histidine decarboxylase knockout; H3R KO, histamine H3 receptor knockout.
Examples of drugs used in histamine research and in clinical trials.
| Mechanism of action | Specificity | Affinity at human vs. rat H3 receptor | Use in clinical studies and possible indication(s) | Reference | |
|---|---|---|---|---|---|
| Ciproxifan | Inverse agonist | H3R | p | No; experimental drug | Ireland-Denny et al. ( |
| Clobenpropit | Inverse agonist | H3R/H4R | p | No; experimental drug | Ireland-Denny et al. ( |
| Thioperamide | Inverse agonist | H3R/H4R | p | No; experimental drug | Ireland-Denny et al. ( |
| ABT-239 | Inverse agonist | H3R | p | No, experimental drug | Esbenshade et al. ( |
| Bavisant (JNJ-31001074) | Neutral antagonist? | H3R? | not disclosed | Yes; ADHD, alcoholism | Kuhne et al. ( |
| GSK189254 | Inverse agonist | H3R | p | Yes, narcolepsy, hyperalgesia | Medhurst et al. ( |
| JNJ-39220675 | Neutral antagonist? | H3R | Yes; allergic rhinitis | Galici et al. ( | |
| Pitolisant (BF2.649) | Inverse agonist | H3R | IC50 = 5.3 nM, | Yes; excessive daytime sleepiness, schizophrenia, epilepsy | Ligneau et al. ( |
| Immepip | partial agonist | H3R | p | No; experimental drug | Ireland-Denny et al. ( |
| R-α-methylhistamine | agonist | H3R | p | No; experimental drug | Ireland-Denny et al. ( |
| precursor of histamine | – | – | No, experimental drug | Verdiere et al. ( | |
| α-fluoromethylhistidine | inhibitor of histidine decarboxylase | – | – | No, experimental drug | Kollonitsch et al. ( |